Theravance Biopharma (TBPH) EBIT Margin (2013 - 2026)
Theravance Biopharma (TBPH) reported EBIT Margin of 53.58% for Q1 2026, up 4022.0% year-over-year from 1.3% in Q1 2025, and down 166.93% quarter-over-quarter from 80.05% in Q4 2025.
Theravance Biopharma (TBPH) EBIT Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBIT Margin data on file, last reported at 53.58% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 53.58%, up 4022.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.52% (up 7840.0% YoY), and the FY2025 annual result was 430.83%, up 50375.0% from the prior year.
- EBIT Margin declined to 53.58% in Q1 2026 per TBPH's latest filing, from 80.05% in the prior quarter.
- Over five years, EBIT Margin peaked at 80.05% in Q4 2025 and troughed at 1540.08% in Q1 2022.
- A 5-year average of 166.72% and a median of 73.44% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin slumped 95165 bps in 2022, then jumped 130093 bps in 2023.
- A 5-year view of EBIT Margin shows it stood at 119.0% in 2022, then soared by 70 bps to 35.53% in 2023, then sank by 38 bps to 49.06% in 2024, then surged by 263 bps to 80.05% in 2025, then plunged by 167 bps to 53.58% in 2026.
- Business Quant data shows TBPH's EBIT Margin at 53.58% in Q1 2026, 80.05% in Q4 2025, and 32.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -53.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.58% |
| Dec 31, 2025 | 80.05% |
| Sep 30, 2025 | -32.29% |
| Jun 30, 2025 | -10.40% |
| Mar 31, 2025 | -93.80% |
| Dec 31, 2024 | -49.06% |
| Sep 30, 2024 | -64.25% |
| Jun 30, 2024 | -110.16% |
| Mar 31, 2024 | -77.27% |
| Dec 31, 2023 | -35.53% |
| Sep 30, 2023 | -55.82% |
| Jun 30, 2023 | -117.27% |
| Mar 31, 2023 | -239.15% |
| Dec 31, 2022 | -119.00% |
| Sep 30, 2022 | -73.44% |
| Jun 30, 2022 | -243.25% |
| Mar 31, 2022 | -1,540.08% |
| Dec 31, 2021 | -375.80% |
| Sep 30, 2021 | -406.36% |
| Jun 30, 2021 | -496.44% |